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1 Introduction 
 
Financial analysis is a series of economic management activities used to analyze and 
evaluate the profitability, operational capacity, solvency and growth capacity related to 
financing activities, investment activities, business activities, financial institutions in past and 
present of the company, which is based on accounting and reporting information, and a series 
of specialized, analytical techniques and methods. In simple terms, by analyzing the financial 
statements, investors can know whether the company is worth investing or borrowing, 
managers know how to make decisions to improve operational efficiency and assess the 
company's past financial performance and forecast the future operating developments of the 
enterprise.  
The GlaxoSmithKline plc (GSK) Company was chosen because of its strong competitive 
performance in the pharmaceuticals industry in worldwide. It is the biggest British 
pharmaceutical company headquartered in Brentford, London and in 2014 it proposed 
three-part transaction with Novartis. The Chief Executive Officer Sir Andrew Witty said it 
will accelerate the strategy of making GSK a simpler, stronger and more balanced platform 
for long-term growth. GSK Company also is the world's eighth largest drugs and biotech 
company as of 2016, after Johnson& Johnson, Pfizer, Novartis, Roche, Sanofi, Merck and 
Bayer.  
The aim of the thesis is to evaluate the financial performance of GSK company for the by 
the help of annual reports for period 2011 - 2015. 
The main content in this thesis is divided into five chapters, while the first one is 
introduction and the last one is conclusion. 
In Chapter 2, there are five main parts of this chapter, goal of financial analysis, source of 
data for financial analysis(including balance sheet, income statement and cash flow statement), 
description of three methods of financial analysis used in this thesis, including common size 
analysis, financial ratio analysis, pyramidal decomposition.  
In Chapter 3, the general idea about the GSK Company’s business scope, history, 
management structure and the team as well as aim and strategies will be presented. Through 
this chapter, you will have the image of what GSK Company looks like in your mind.  
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Chapter 4 is the most important part of the thesis. Data from counting materials mentioned 
before in period 2011 to 2015 of GSK Company will be used. The results of common size 
analysis, financial ratios and pyramidal decomposition of return on equity will be presented 
with the tables and figures to provide us with the more vivid idea about the financial trend of 
GSK Company.  
In the last chapter, the general conclusion will be summarized about what is the company 
financial situation in the past, which aspects need to be improved, how GSK Company will 
develop in the future. 
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2 Description of the Financial Analysis Methodology 
 
In this chapter, we will first illustrate the goal of financial analysis, then describe the 
source of the financial data (balance sheet; cash flow; income statement). Last but not least, in 
the third part of this section we will provide the overall of financial analysis methodology, 
namely, common-size analysis, financial ratio analysis, and DuPont analysis. This chapter is 
based on Dluhošová (2014) and Robinson (2015). 
 
2.1 Goal of financial analysis 
 
Financial analysis is a series of economic management activities to analyze and evaluate 
the financial situations of the company.  
To understand the industry's general production and management pattern we usually 
analysis companies in the same industry. Because different industries have different needs for 
the occupation of funds. For example, there is a significant difference in cash liquidity 
between retail industry and heavy industry. The supermarkets usually have a higher ratio of 
cash while car manufacturing has more fixed assets. 
By comparing with the industry data, enterprise financial ratios help enterprises 
understand the advantages and disadvantages of enterprises, which were reflected in the 
indicators of enterprise solvency, profitability and other ratios. Through the comparison 
between relevant indicators, a corporation enables to locate their status in the market, find out 
management problems, thus to make the enterprise management and development strategies. 
In addition to industry data compare, the two companies in same industry also compare 
the ratios in business operation process, which contributes to understanding the strengths and 
weaknesses of competitors, identifying gaps, in order to take an effective competitive strategy. 
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2.2 Source of data for financial analysis 
 
Financial statements (or financial report) is a set of accounting documents, which reflects 
a business financial performance over a financial period (mainly quarterly or annual), and the 
situation in the end. It is quantified by the financial data. Financial statements can help 
investors and creditors understand the business situation of enterprises and further help 
economic decision-making. The financial statements are based on generally accepted 
accounting principles to report the financial position selectively and are an approximate 
description of the real economic situation. They typically include basic financial statements, 
accompanied by a management discussion and analysis. 
These three statements are: 
An income statement, also known as a statement of revenue & expense, profit and loss 
report, which reports on a company's income, expenses, and profits over a period of time. A 
profit and loss statement provides information on the operation of the enterprise, including 
sales and the various expenses incurred during the stated period. 
A balance sheet referred to as a statement of financial position, reports on a company's 
assets, liabilities, and owner’s equity at a given point in time. 
A cash flow statement reports on a company's cash flow activities, particularly its 
operating, investing and financing activities. 
 
2.2.1 Balance sheet 
 
The balance sheet provides the information about a company's assets, liabilities and 
shareholders' equity at a specific point in time. The image 2.1 shows the structure of balance 
sheet. 
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Image 2.1 Balance sheet format 
 
Source: 
http://www.creditmanagement-tools.com/understand-and-analyze-the-balance-sheet-c1-r13.ph
p 
 
As shown in the image 2.1, the right sides provided information about where the 
company's assets come from, borrowing or shareholder investment? The liabilities are the 
financial resourced owned by external borrowers, such as banks. The shareholders’ equity are 
the financial resources owned by the company or say by the shareholders, which includes 
paid-in capital, retained earnings, reserves and so on. The left side refers how the company's 
funds are used. Is it used to the investment in land equipment or the purchase of raw materials? 
The assets are usually divided into current assets and fixed assets according to weather the 
assets can be quickly converted into cash or cash equivalents, such as accounts receivable. 
The current assets refers to investments with short maturity (usually shorter than one year), 
strong liquidity, easy conversion to known amounts of cash, and very little risk of change in 
value, such as inventories. But the fixed assets have a longer life cycle and cannot be 
converted into cash quickly and in most of the time the converting process companies with 
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the loss. For example, if a company wants to sell its property or plant in a relatively short time, 
the price must be lower than its actual prize, because of the lack of time for discovering the 
value.  
The money invested in the company should be equal to the company’s total assets, as the 
following formula: 
 equitysrShareholdesLiabilitieAssets 　'  (2.1) 
2.2.2 Income statement 
 
How the managers and investors know whether the company make any profits or not in a 
certain period. One financial statement that provides this information is income statement. 
Unlike the balance sheet which represents a single moment in time, income statement (P/L 
statement) is a dynamic report that represents a period of time like the cash flow statement. 
The detailed structure is provided in the following image. 
 
Image 2.2 Income statement format 
 
Source: http://financialstatementform.org/10-what-is-the-purpose-of-an-income-statement/. 
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Image 2.2 provided the basic structure of income statement; the internal relationshipis 
showed the equation below. 
 ExpensesvenuesincomeNet  Re　   (2.2) 
The first component listed in the income statement is sales, then sales minus cost of sales 
derived gross profits; after subtracting selling, general and administrative costs derived 
operating profit (or loss); then minus non-operating expenses, such as depreciation, interest 
and tax, we get the net profit (loss).  
The profit and loss statement can provide the readers with the relevant information 
needed to make reasonable economic decision-making. By analyzing the changes in net profit 
among the past few years, investors can learn about company’s profitability in the past and 
even forecast its profitability performance in future, thus decided whether to invest the 
company or not. It can also be used to analyze the reasons for the change of profit. For 
instance, the decline of profit may due to the increase in company's financing costs or decline 
of sales or any other causes. Specific circumstances need to analysis the specific company's 
statement. 
 
2.2.3 Cash flow statement 
 
The cash flow statement reflects the inflow and outflow of during an accounting period. 
The money invested into the business is called cash inflows, and the funds come out of the 
business are called cash outflows. The cash flow statement can be used to analyze whether a 
firm or institution has sufficient cash to meet the expenses in the short term. The cash flow 
statement is intended to reflect the impact of the various items in the balance sheet of cash 
flows and to classify them into three categories: business, investment and financing, 
depending on their use. As shown below: 
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Image 2.3 Cash flow statement  
 
Source: http://credit-help.pro/forex/31674. 
 
As shown in the image, the basic equation in cash flow is: 
 outflowsotallowsTotalflowcashNet 　　　　　 Tinf   (2.3) 
Operating activities section includes the cash flows derived out from an enterprise’s daily 
business activities such as production, sales and delivery of the company's product as well as 
collecting payment from the customers. In more specific words, operating outflows includes 
payments for inventory purchases, wages and salaries, taxes and so on; operating inflows 
includes sales of goods or services, interest revenues and so on. 
Cash flows from investing activities refer to examples of cash flow operations that can 
affect the business of non-current assets investment, including the sale and purchase of fixed 
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assets such as equipment and housing. Cash inflows from investing activities are usually 
derived from the recovery of investments and the sale of fixed assets and intangible assets. 
Cash outflows include and purchase of fixed assets and intangible assets and investments. 
Funding activities refer to activities that lead to changes in the size and structure of 
corporate capital (the paid-in capital and capital reserve in the owner's equity of the balance 
sheet) and the debt (short-term borrowings and long-term borrowings and bonds payable). 
Cash flows from financing activities refer to cash flows from operations that affect business 
equity and debt. Examples of such operations include the issuance and recovery of equity 
securities and debt securities. 
 
2.3 Common-size analysis 
 
The common-size analysis is a tool used for evaluation of a company’s performance by 
providing ratios calculated from financial statements. The common size analysis makes it 
possible for a company to compare its performance with peers and evaluate the company’s 
performance by comparing data in previous time. There are two types of common-size 
analysis: vertical common-size analysis andhorizontal common-size analysis. 
 
2.3.1 Vertical common-size analysis 
 
The vertical common-size analysis is an analysis of the changes in the proportions of 
selected benchmarks (total revenues, total assets, total liabilities, etc.). Compared with 
horizontal common-size analysis method, the vertical common-size analysis focus on the 
composition of given financial statement. The result is expressed as a percentage proportion,  
in which the data is divided by a given base. For example, on income statement analysis, the 
base is usually given by total revenues. In the balance sheet analysis, the base is usually given 
by total revenues.  
  
13 
 
The basic relationship is 
 .
　　
　　
benchmarkofAmount
itemofAmount
Percentage   (2.4) 
 
2.3.2 Horizontal common-size analysis 
 
The horizontal common-size analysis focuses more on the change of the data, both 
absolute change and percentage change. Horizontal common-size analysis helps to solve two 
problems. Firstly, by comparing the data with the same trade or business, it helps to determine 
a company’s position and make future decisions. Secondly, comparing the data with previous 
periods, which helps to understand the corporation performance over the years, in-depth 
analysis the long-term trend of company performance and made predictions of the 
development of corporation. In the practical financial analysis, we usually use a given year as 
a basis, then calculate the absolute change or relative change to compare the performance 
during the past period. 
The formula of absolute change and relative change as below 
 UUU ttchangeAbsolute  0-　  (2.5) 
 
U
U
U
UU ttchangelative
00
0
-
　Re

  (2.6)
 
Where U t  represents the amount of the item in comparison year, and 0U  represents the 
amount of the item in base year. 
In the horizontal common-size analysis, it is also important to take all possible changes in 
specific economic conditions into consideration, such as inflation, taxation, etc. 
 
2.4 Financial ratio analysis 
 
Financial ratio analysis is a quantitative analysis of the information contained in the 
company's financial statements and compares the financial data in the form of financial ratios 
to assess the company's financial status. If the company's stock is traded on a financial market, 
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the market price of the stock is used as financial data. There are four kinds of ratios in this 
chapter classified according to their targets and focus, namely, profitability ratios, liquidity 
ratios, solvency ratios and activity ratios. 
 
2.4.1 Profitability ratios 
 
Profit is the main goal of business; therefore, profitability analysis is an important part of 
financial analysis. Profitability analysis refers to the ability of an enterprise to make a profit 
within a certain period of time.  
The size of the profitability is a relative concept, that is, the profit is relative to a certain 
amount of resources and a certain amount of income. The higher the profit margin, the 
stronger the profitability company has. Profitability is the source of funds for the investor to 
obtain investment income, creditors receive the principal and interest, is the embodiment of 
the business managing ability. And it is usually evaluated by the following ratios: operating 
profit margin, net profit margin, return on assetsand return on equity. 
 
Operating profit margin 
Operating profit margin refers to the ratio of operating profit and operating income of an 
enterprise. It is an indicator to measure business efficiency, reflecting the ability of enterprise 
managers to obtain profits without considering the non-operating costs. Operating profit is the 
difference between operating revenues and operating expenses. When a firm does not have 
non-operating income, then operating income is sometimes used as an EBIT (Earnings before 
interest and taxes) and operating profit. EBIT is a firm's profit that includes all expenses 
except interest and income tax expenses. 
The operating profit margin is calculated as: 
 
 salesNet
EBIT
venues
incomeOperating
inmprofitOperating
　
　
　　 
Re
arg  (2.7) 
 
Net profit margin is the percentage of net profit to sales revenue. This indicator reflects 
the net profit from each dollar's sales revenue, indicating the level of revenue from sales 
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revenue. 
It is proportional to the net profit, inversely proportional to sales revenue. At the same 
time when enterprises increase their sales revenue, enterprises must obtain corresponding 
more net profit in order to make the net profit margin remains unchanged or improved. By 
analyzing the ups and downs of sales net profit margin, you can encourage enterprises to 
expand sales and pay attention to improve management, improve profitability simultaneously. 
Generally, the greater the index, the stronger the profitability corporate has in sales. If a 
business can maintain a good sustained growth in the net profit margin, it should be said that 
the financial situation of enterprises is good, but not absolutely speaking, the greater the better 
sales net profit margin, but also must see the company's sales growth and net profit changes. 
The net profit margin is calculated as: 
 venues
EAT
vrnues
profitNet
inmprofitNet
ReRe
arg 
　
　　  (2.8) 
 
Return on assets 
Return on assets (ROA) is used to measure how much net profit was created by per unit 
of assets, can also be interpreted as the ratio of corporate profits to the average assets of 
enterprises. 
Return on assets is an indicator that reflects the comprehensive utilization of assets. It is 
also an important indicator that measures the profitability of enterprises using the total 
amount of creditors and owners' equity. The higher the yield of assets, the higher the 
efficiency of asset utilization, which means the profitability of the whole enterprise is stronger 
and the management level of the enterprise is better. In contrast, the lower the asset return, the 
less the utilization efficiency of the enterprise assets, the less profit are created by the same 
assets, the worse profitability of the whole enterprise, the lower the level of business 
management. 
ROA can be computed as: 
 Assets
EAT
assetsTotal
incomeNet
ROA 
　
　
 (2.9) 
 
Return on equity 
16 
 
Return on equity (ROE) refers to the ratio of net profit after tax to equity investment. It is 
an indicator of the return on investment relative to shareholders' equity, reflecting the 
company's ability to generate net profit using the net asset. The calculation is based on the net 
profit after tax deducting the preferred dividend and the special income then divided by the 
shareholders' equity. This ratio calculating the return on investment of the company's common 
shareholders is an important indicator of the profitability of listed companies. 
However, the company's high return on equity does not mean strong profitability. Some 
industries do not need too much investment in assets, therefore they usually have higher ROE, 
such as consulting firms. Some industries need to invest a lot of infrastructures to generate 
profits, such as refineries. Therefore, you cannot determine the company's profitability single 
to ROE. In general, the capital-intensive industry has a higher threshold for entry and less 
competition. On the contrary, industries with high ROE but low assets are easier to enter but 
face greater competition. Because of this reason, ROE should be used to compare the same 
industry. 
ROE can be computed as: 
 Equity
EAT
equitysrshareholde
incomeNet
ROE 
　
　
'
 (2.10) 
 
2.4.2 Liquidity ratios 
 
Whether the enterprise has the ability to pay in cash and the ability to repay the debt is 
the key to the healthy survival and development of the enterprise. Liquidity ratios are used to 
assess the safety of corporate liabilities and the ability of an enterprise to repay its short-term 
debt. These ratios are mainly current ratio, quick ratio and cash ratio and each of them has its 
special emphasis. The details are described below. 
 
Current ratio 
The current ratio is the most common indicator of the company's short-term solvency. 
The current ratio is the ratio of current assets divided by current liabilities. It not only 
represents the degree of security of short-term creditor claims but also reflects the ability of 
17 
 
enterprises to operate capital.  
The higher the ratio, the stronger the short-term solvency of the company and the 
sufficient working capital of the company; conversely, the company's short-term solvency is 
not strong or funding is not sufficient. Generally, perfect financial companies, their current 
assets should be much higher than the current liabilities, at least not less than 1:1, generally 
considered greater than 2:1 is more appropriate. However, from companies and shareholders 
perspective, this ratio is not the higher the better. The excessive accounts receivable and 
inventory balances can lead to high current ratio, which does not mean excel financial 
situation.In contrast, it may be harmful to financial soundness. When the ratio is higher than 
5:1, it means that the company's assets are not fully utilized. 
The formula is as follows: 
 sliabilitieCurrent
assetsCurrent
ratioCurrent
　
　
　   (2.11) 
 
Quick ratio 
Although the liquidity ratio can be used to assess the overall liquidity of liquidity, people 
(especially short-term creditors) want to obtain a further ratio of liquidity to assess the 
liquidity. This indicator is called the quick ratio, used to measure the company's clearing 
capacity. Investors can detect the ability of a company to pay a short-term debt in a very short 
period of time by analyzing the quick ratio. 
It is generally believed that the normal quick ratio is 1 if the quick ratio is less than 1 will 
be considered short-term solvency is low. Generally, the minimum speed ratio is 0.5:1, and if 
it keeps at 1:1, the safety of current liabilities is more secure. Because, when this ratio reaches 
1:1, even if the company's cash face difficulties, it will not affect the immediate solvency. 
This is just a general view because various industries have very different speed ratios, there is 
no uniform standard. For example, in cash-operated stores, there are almost no receivables, 
the quick ratio is much lower than 1. On the contrary, some enterprises with more accounts 
receivable may have a quick ratio of more than 1. 
The formula is as follows: 
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 sliabilitieCurrent
sInventorieassetsCurrent
ratioQuick
　
　
　


 (2.12)
 
Cash ratio 
The cash ratio is the ratio of a company's total cash and cash equivalents to its current 
liabilities. The higher the cash ratio, the higher the cash assets accounted for the current assets, 
the lower risk of realization loss. The cash ratio is generally a more conservative look at a 
company's ability to cover its liabilities than many other liquidity ratios because other assets, 
including accounts receivable, are left out of the equation. 
The formula is as follows: 
 sliabilitieCurrent
sequivalentCashCash
ratioCash
　
+
=　  (2.13) 
 
2.4.3 Solvency ratios 
 
The solvency of an enterprise, static speaking, is the ability to use corporate assets to pay 
off corporate debt; dynamic speaking is the capacity to repayment the debt by using corporate 
assets and running a business. The solvency of an enterprise refers to the ability of an 
enterprise to repay its long-term debt with its assets. 
The solvency ratios are also called as leverage ratios. Two ratios will be mentioned below: 
debt to assets ratio and debt to equity ratio. 
 
Debt to assets ratio 
The debt-to-assets ratio reflected the proportion of capital provided by the creditor to the 
total capital, therefore is a comprehensive indicator of the company's debt levels and it is 
generally positively correlated with the long-term solvency of the firm. 
It can also be used to measure the level of protection of creditors' rights when the 
company faces liquidation problems. It is also an index used to measure the ability of 
companies of using funds of the creditors to carry out business activities as well as the degree 
of security of creditors to issue loans.If the asset-liability ratio reaches 100% or more than 
100%, it means that the company has no net assets or insolvency. 
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The formula is as follows:  
 assetsTotal
debtTotal
ratioassetstoDebt
　
　
　   (2.14) 
 
Debt to equity ratio 
The debt-to-equity ratio used to measure the company's financial leverage shows the 
proportion of equity and debt in the company's assets. Creditors and investors pay great 
attention to the debt-to-equity ratio, as it shows how much the company's managers are 
willing to borrow, rather than using their own share capital. Lenders such as banks are 
particularly sensitive to this ratio because an excessive debt-equity ratio will make them face 
the risk of loans that cannot be recovered. Faced with this risk, banks tend to use a restrictive 
contract to force companies to pay their debts with excess cash flow. It is very common to use 
extractive requirements as well as to require investors to invest more of their own capital. 
It may be more meaningful to compare the debt-to-equity ratios of different companies in 
the same industry. The debt-to-equity ratio reflects the contrast between the funds provided by 
the creditor and the funds provided by the shareholders. The lower the ratio, the better the 
long-term financial position the firm has and the protection of the creditor's rights are better. 
The ratio should generally be less than 1. 
The formula is as follows: 
 equityTotal
debtTotal
ratioequitytoDebt
　
　
　   (2.15) 
Interest coverage 
The interest coverage ratio is a measure of a company's ability to meet its interest 
payments.High interest coverage ratio means that creditors have a comfort level with 
companies that can easily service debt interest payments. This ability usually means the 
strong profitability and high liability level.The interest coverage ratio is calculated by 
dividing      a company's earnings before interest and taxes (EBIT) during a given period 
by the amount of interest payment on its debts during the same period. 
As the following formula calculate: 
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paidInterest
frofitOperating
erageInterest
　
　
　　 cov  (2.16) 
 
2.4.4 Activity ratios 
 
The activity ratios are financial ratios used to measure the efficiency of the company's 
asset management. There are some ratios that focus on several specific assets, such as 
inventory or accounts receivable while some other ratios focus on the overall efficiency of the 
firm. Here we mainly discuss the three operating activities ratio: inventory turnover, accounts 
receivable turnover and total asset turnover. 
Inventory turnover 
The inventory turnover represents the ratio of the cost of goods sold to the average 
inventory for a certain period of time used to reflect the turnover rate of inventory, the 
liquidity of inventory and measure whether the capital occupancy of inventory is reasonable. 
The analysis of inventory turnover helps to enhance the efficiency of the use of funds and the 
short-term solvency of the enterprises to ensure the continuity of production and operation. 
Inventory turnover rate is a supplementary explanation of the current assets turnover rate. 
Through the calculation and analysis of inventory turnover rate, it is possible to measure the 
turnover rate of inventory assets in a certain period of time which reflects the efficiency of 
purchasing, producing and selling enterprises. The higher the inventory turnover, the stronger 
the liquidity of the enterprise's inventory assets, the faster the turnover of capital spent on 
inventories. 
The formula is as follow: 
 inventoryAverage
soldgoodsofCosts
turnoverInventory
　
　　　
　   (2.17) 
 
Accounts receivable turnover 
Accounts receivable turnover, also known as the collection ratio is the average times of 
accounts receivable converted into cash over a period of time (usually in one year), which is 
used to measure the degree of liquidity of corporate accounts receivable. Accounts receivable 
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turnover is the ratio of sales revenue divided by the average receivables, that is, the average 
number of accounts receivable into cash in the year, which indicates the rate at which 
accounts receivable flows.  
The formula is as follow: 
 receivableAccounts
venus
turnoverreceivableAccounts
　
　　
Re
  (2.18) 
 
Total assets turnover 
The total asset turnover is the ratio of the sales income to the total assets of the enterprise 
over a certain period of time, which is an important indicator for comprehensively evaluating 
the quality of operation and use efficiency of all the assets of the enterprise. The greater the 
turnover rate indicates that the faster the total asset turnover, reflecting the stronger sales 
capacity. Enterprises can accelerate the turnover of assets to get an increase in the absolute 
amount of profits through the small profits but quick turnover.  
The purpose of inventory turnover analysis is to find out the problems in inventory 
management from different perspectives and links, so that inventory management can ensure 
the production and operation continuity at the same time, as little as possible to take up 
operating funds, improve the efficiency of the use of funds, solvency, and promote the 
improvement of enterprise management level. In general, it improves management level of 
the enterprise. 
The total asset turnover is calculated as: 
 assetsTotal
venues
turnoverassetsTotal
　
　　
Re
  (2.19) 
 
2.5 DuPont analysis  
DuPont analysis enables to analysis the financial situation of enterprises synthetically, by 
using the relationship between several major financial ratios. The name comes from the 
DuPont Corporation that started using this formula in the 1920s. The basic idea is to 
decompose the return on assets of enterprises into a number of financial ratio products, which 
will help in-depth analysis and comparison of business performance. Through decomposition 
of the target ratio, we are allowed to in-depth analysis which component ratio contributed 
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most to the target ratio’s change and focus on improving the most influential factor. The 
DuPont analysis is a classic method used to evaluate corporate performance from a financial 
point of view of the company's profitability and level of return on shareholders' equity. This 
sector is based on Zmeškal (2004). 
The following formula is a fundamental example of the pyramidal decomposition in the 
DuPont analysis: 
 
Equity
assetsTotal
assetsTotal
venues
venues
EAT
Equity
EAT
ROE
　
•
　
Re
•
Re
==  (2.20)
 
 
In this formula, the ROE ratio is broken into three component ratios: net profit margin 
(EAT/revenues) measures profitability; assets turnover (revenues/total assets) measures asset 
use efficiency, and equity multiplier (total assets/equity) measures financial leverage. 
With this method, we enable to analyze indicators, whose change have caused the change 
in the basic ratio and quantify each component ratio's contribution to the change in basic ratio. 
In addition, if we want to separate the effects of taxes and interest, the profit margin can 
be decomposed as follows: 
 venues
EBIT
EBIT
EBT
EBT
EAT
venues
EAT
Re
••=
Re
 (2.21) 
 
In this formula, the net profit margin is broken into three component ratios: tax burden 
(EAT/ EBT); interest burden (EBT/EBIT) and operating margin (EBIT / Revenue)  
There are five methods for quantification of influence: 
 Methods of gradual changes; 
 Methods of decomposition with surplus; 
 Logarithmic decomposition method; 
 Functional decomposition method; 
 Integral method. 
Here we only introduce some of them. 
 
Method of gradual changes 
The method concentrates on working with absolute changes in component ratios. The 
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advantage of the method is that it can be applied regardless of positive or negative values in 
component ratio or basic ratio and the disadvantage is that the different order in component 
ratios can cause different results. 
The formula is following:  
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Symbols: X - basic ratio, X - absolute change in the basic ratio, a - component ratio,  
a - absolute change in the component ratio, X a1Δ
- absolute change in the basic ratio caused 
by the change in the an component ratio. 
 
Method of logarithmic decomposition 
This method only includes one formula to quantify the impact regardless of how many 
component ratios and impact of the i -the component ration on the change in the basic ratio is 
calculated as follows: 
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Symbols: x -basic ratio, aix - absolute change in the basic ratio, x
x
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= - index of change in 
basic ratio,
a
a
I a
0,1
1,1
= - index of change in component ratio. 
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3 Profile of the Company GSK 
In this section, we will provide an overview of GlaxoSmithKline plc (GSK) including its 
business scope, history, structure, management structure and its achievement.  
GlaxoSmithKline plc is a British pharmaceutical company headquartered in Brentford, 
London, established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham.GSK 
was the world's tenth largest pharmaceutical company as of 2016, after Johnson & Johnson, 
Pfizer, Novartis, Roche Holding, Sanofi, Merck& Co., Bayer. Andrew Witty has been the 
chief executive officer since 2008. 
The company has a primary listing on the London Stock Exchange and is a constituent of 
the FTSE 100 Index. As of November 2016, it had a market capitalization of £74 billion, the 
fifth largest on the London Stock Exchange. It has a secondary listing on the New York Stock 
Exchange. 
GSK's drugs earned £14.2 billion occupied 60% and vaccines earned £3.7 occupied 
15%of group turnover in 2015.GSK's consumer products, which earned £6 billionin2015, 
include wellness, oral health nutrition and skin health. GSK has a deep portfolio of innovation 
focused on six core areas of scientific research and development: HIV and infectious diseases, 
oncology, immune-inflammation, vaccines, respiratory and rare diseases. In 2015, they 
profiled around 40 new potential medicines and vaccines, 80% of which are believed have the 
potential to be first-in-class. This means they may offer benefits beyond current standards of 
care and, in some cases, could radically transform how patients are treated. 
 
3.1 Company business scale 
 
GlaxoSmithKline is a science-led global healthcare company. GlaxoSmithKline research 
and develop a broad range of innovative products in three primary areas of Pharmaceuticals, 
Vaccines and Consumer Healthcare. It has a significant global presence with commercial 
operations in more than 150 countries, a network of 89 manufacturing sites, and large R&D 
centers in the UK, USA, Belgium and China. 
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Pharmaceuticals 
Their Pharmaceuticals business develops and makes medicines to treat a broad range of 
acute and chronic diseases. They have leading positions in respiratory disease and HIV with a 
portfolio of innovative and established medicines.  
Vaccines 
Their Vaccines business is one of the largest in the world, developing, producing and 
distributing over 1.9 million vaccines every day to people across the world. They have a broad 
portfolio of 39 paediatrics, adolescent, adult and travel vaccines. In 2015, GSK distributed 
more than 690 million doses to over 150 countries.  
Consumer Healthcare 
Their Consumer Healthcare business develops and markets products in Wellness, Oral 
health, Nutrition and Skin health. They have a portfolio of some of the world’s most trusted 
and bestselling brands which include Sensodyne, Voltaren, Horlicks and Panadol. 
 
3.2 Company History 
 
The merger between Glaxo Wellcome and SmithKline Beecham was announced 
completed in December 2000, forming GlaxoSmithKline (GSK).Glaxo Wellcome was 
founded in the 1850s as a general trading company in Bunnythorpe, New Zealand, by a 
Londoner, Joseph Edward Nathan. Glaxo Laboratories opened new units in London in 1935. 
After the company bought Meyer Laboratories in 1978, it began to play an important role in 
the US market. In 1983 Glaxo Inc., moved to Research Triangle Park and Zebulon in North 
Carolina. 
Burroughs Wellcome&Company was founded in 1880 in London by the American 
pharmacists Henry Wellcome and Silas Burroughs. The company moved to Research Triangle 
Park in North Carolina in 1971. Glaxo and Burroughs Wellcome merged in 1995 to form 
Glaxo Wellcome. By 1999 Glaxo Wellcome had become the world's third-largest 
pharmaceutical company by revenues (behind Novartis and Merck), with a global market 
share of around 4 per cent. The company had R&D facilities in Hertfordshire, Kent and 
London, and manufacturing plants in Scotland and the north of England. It had R&D centres 
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in the US and Japan, and production facilities in the US, Europe and the Far East. 
SmithKline Beecham 
In 1843 Thomas Beecham launched his Beecham's Pills laxative in England, giving birth 
to the Beecham Group. By the 1960s Beecham was extensively involved in pharmaceuticals. 
John K. Smith opened its first pharmacy in Philadelphia in 1830. In 1865 Mahlon 
Kline joined the business, which 10 years later became Smith, Kline & Co. In 1891 it merged 
with French, Richard and Company, and in 1929 changed its name to Smith Kline & French 
Laboratories as it focused more on research. SmithKline & French merged with Beckman Inc. 
in 1982 and changed its name to SmithKline Beckman. In 1988 it bought its biggest 
competitor, International Clinical Laboratories, and in 1989 merged with Beecham to form 
SmithKline Beecham plc. The headquarters moved from the United States to England. 
 
3.3 Company’s mission and strategy 
 
GSK company said that their mission is to help people do more, feel better, live longer. 
The company management team focused on delivery of their strategic priorities which 
aim to increase growth, reduce risk and improve the company’s long-term financial 
performance. These priorities are: grow a balanced global business, deliver more products of 
value, simplify the operating model and be a responsible business. In order to achieve the 
aims, they made some strategic responses. 
To grow a balanced global business, GSK centre on three business areas of 
Pharmaceuticals, Vaccines and Consumer Healthcare. By creating a more balanced business 
and product portfolio, the company’s capable of delivering sustainable sales and earnings 
grow and return to shareholders are improved. 
To deliver more products of value, the research and development organisation has been 
reorganized aim to improve productivity and rates of return in research and development 
department so that it is better able to sustain a pipeline of products that offer valuable 
improvements in treatment for patients and healthcare providers. 
To simplify the operating model, GSK transforms its operation so that the company can 
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reduce complexity and become more efficient. For example, the number of board members 
declined from 16 in 2015 to 12 in 2016. This frees up resources to reinvest elsewhere in the 
business or return to shareholders. 
GSK also believed that being a responsible business is central to strategies, and the 
company want to ensure their values are embedded in their culture and decision-making 
which helps them better meet the expectations of society. 
 
3.4 Achievements 
 
In 2015, GSK invested £3.1 billion in search to develop new medicines vaccines and 
consumer products. 
They profiled around 40 new potential medicines and vaccines in the pipeline at research 
and development (R&D) event in 2015, 80% of which are believed potentially first-in-class. 
GSK have a network of 89 manufacturing sites, and large R&D centres in the UK, US, 
Belgium and China. 
6 billion albendazole tablets donated to eliminate two neglected tropical diseases, 
reaching over 760 million people. 
More than 11,000 people work in R&D in searching for new medicines, vaccines and 
consumer healthcare products. 
In 2015, GSK distributed more than 690 million doses of vaccines around the world. 
GSK employ around 101,000 people in over 150 countries, with more than a third of these in 
emerging markets. 
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4 Evaluation of the Financial Situation of the Company 
 
This practical part is focused on analyzing the GlaxoSmithKline plc. This chapter is 
divided into three sections according to aforementioned analysis methods: common-size 
analysis (including both vertical and horizontal), financial ratio and decomposition analysis. 
All figures come from the annual reports of GlaxoSmithKline plc. during the period from 
2011 to 2015. Some pharmaceutical industry data in the United Kingdom will also be used to 
analyze the company's financial performance and compare it with the industry average. 
 
4.1 Common-size analysis 
 
The common-size analysis can be divided into two parts: vertical common-size analysis 
and horizontal common-size analysis. In this section, we use these two methods to analysis 
the trends and major characteristics of GSK’s financial situation in recent five years. 
 
4.1.1 Vertical common-size analysis 
 
Based on the balance sheet of GSK, according to equation 2.4, all individual assets or 
groups of assets are shown as a percentage of total assets. It shows in Tab. 4.1. 
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Table 4.1 Vertical common-size analysis of balance sheet 
 2011 2012 2013 2014 2015 
Current assets  39% 33% 36% 36% 31% 
Trade and other receivables  14% 13% 13% 11% 11% 
Cash and cash equivalents  14% 10% 13% 11% 11% 
Inventories 9% 10% 9% 10% 9% 
Other Current assets 2% 0% 1% 4% 0% 
Non-current assets  61% 67% 64% 64% 69% 
Property, plant and equipment 21% 21% 21% 22% 18% 
Goodwill and other intangible assets 28% 35% 32% 30% 41% 
Deferred tax and other non-current assets 13% 11% 11% 12% 10% 
Total assets 100% 100% 100% 100% 100% 
Source: Our elaboration 
 
In Tab. 4.1, we can see the assets structure keep stable in general during the last five years. 
Non-current assets increased steadily from 61% in 2011 to 69% in 2015. The total value of 
current assets remains steady during the five years, due to the increase in total assets, the 
proportion declined by 8%, from 39% in 2011 to 31% in 2015. 
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Figure 4.1 Vertical common-size balance sheet of GSK 
 
Source: Own elaboration 
 
Now we can easily see from Fig. 4.1 that each part has experienced their own changes 
through the period. The yellow part is goodwill and other intangible assets, which account for 
most and changed most. The ratios of this part to total assets are 28% in 2011, while in 2015 it 
increased to 41%, which contributes the biggest increments of non-current assets. Goodwill 
increased during the year 2014-2015 reflected the goodwill arising from the acquired Novartis 
Vaccines business and the creation of the Consumer Healthcare Joint Venture.Other intangible 
assets include the cost of intangibles acquired from third parties and computer software. The 
increase in 2015 reflected the impact of acquiring the Vaccines business and the creation of 
the Consumer Healthcare Joint Venture. 
The following part is property, plant and equipment (21%~18%) and deferred tax and other 
non-current assets (13%~11%). The value of these two was on the rise but the percentage was 
in decline. As a pharmaceutical company, the business is science-based, technology intensive 
and highly regulated by governmental authorities. Plenty of financial resources need to 
beused the renewal and maintenance of the company’s property, plant and equipment to 
minimize risks of interruption of production and to achieve compliance with regulatory 
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standards. 
Current assets have three main compositions: cash and cash equivalents, trade and other 
receivables, and inventories. The percentage of inventories was roughly unchanged, at around 
9%. The proportion of both cash and cash equivalents and trade and other receivables had a 
slight drop, from 14% in 2011 to 11% to 2015; inventories, 24% in 2011 and 28% in 2015. 
Then we concentrate on liabilities and assets, the percentage is showed in Tab. 4.2. 
 
Table 4.2 Vertical common-size analysis of balance sheet 
 2011 2012 2013 2014 2015 
Trade and other payables  18% 19% 20% 20% 17% 
Short-term borrowings  7% 9% 7% 7% 2% 
Short-term provisions 8% 2% 2% 3% 3% 
Others current liabilities 4% 3% 3% 3% 3% 
Total current liabilities  37% 33% 32% 33% 25% 
Long-term borrowings 30% 35% 37% 39% 29% 
Pensions and other post-employment benefits  8% 7% 5% 8% 6% 
Others non-current liabilities 5% 8% 7% 8% 24% 
Non-current liabilities 42% 50% 49% 55% 58% 
Total liabilities 79% 84% 81% 88% 83% 
Shareholders’ equity 20% 14% 17% 10% 10% 
Non-controlling interests  2% 2% 2% 2% 7% 
Equity 21% 16% 19% 12% 17% 
Source: Own elaboration 
 
In Tab. 4.2, we can also know the liabilities account for around 80%~90% in total assets, 
which means the major capital resources come from borrowing. The proportions fluctuate 
mildly during the last five years. And the general trend of liabilities proportion was upward. 
As for liabilities composition, the chart shows that the non-current liabilities is the major part, 
which increased by 16%, from 42% to 58% during the period. Total current liabilities 
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proportion fell from 37% in 2011 to 25% in 2015. Despite the fluctuation, the general trend of 
equity proportion was downward. The proportion of shareholder's equity, the largest equity 
composition part, dropped from 20% to 10%. 
 
Figure 4.2 Vertical common-size analysis of balance sheet 
 
Source: Own elaboration 
 
From the Fig. 4. 2 we can learn that the proportion of shareholder’s equity, the largest 
equity composition part, dropped from 20% to 10%. The non-controlling interests bottomed 
out at 2% before 2015, as shown in the graph, 2015 saw a steep increase, rising to 7%. The 
main part of non-current liabilities is long-term borrowings, the proportion of which rise from 
30% to 39%steadilybefore 2015.In 2015, it accounts for 29%.Pensions and other 
post-employment benefits remained steady for five years. Other non-current liabilities 
bottomed out for four years and peaked at 24% in 2015, almost three times more than the 
number in 2004. The reason why other non-current liabilities grew so markedly in 2015 is that 
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more than $20 billion of assets. The transaction, which includes GSK buying Novartis' 
vaccines business for 7.1 billion dollars, Novartis purchasing GSK's cancer drugs for 16 
billion dollars, and the two groups tying up in consumer healthcare, was unveiled in April. 
As shown in the Tab. 4. 2, trade and other payables was the main part of the current 
liabilities, accounting for around 19%. The short-term borrowings reached a plateau in 2011 
around 8%, before declining suddenly in 2015 to 2%. Another significant change is the 
proportion of short-term provisions fell from 8% to 2% then bottomed out at 2% till 2015. 
Then we will analyze the income statement, the table below is a short version of the income 
statement. The below Tab. 4.3 is the component percentage in the income statement. The data 
come from GSK’s income statement between 2011 and 2015. 
 
Table 4.3 Vertical common-size analysis of income statement  
 2011 2012 2013 2014 2015 
Turnover 100% 100% 100% 100% 100% 
Cost of sales 27% 30% 32% 32% 37% 
Selling, general and administration 32% 33% 32% 36% 39% 
Research and development 15% 15% 15% 15% 15% 
Royalty and other operating income 2% 6% 6% -2% 34% 
Total costs 71% 72% 73% 84% 57% 
Operating profit 29% 28% 27% 16% 43% 
Non-operating revenues 3% 0% 1% 0% 4% 
Non-operating cost 3% 3% 3% 3% 3% 
Profit before taxation 28% 25% 25% 13% 44% 
Taxation 8% 7% 4% 1% 9% 
Profit after taxation for the year 20% 18% 21% 12% 35% 
 
Source: Own elaboration 
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Figure 4.3 Vertical common-size analysis of income statement  
 
Source: Own elaboration 
 
In Tab. 4.3 and Fig. 4.3, we can see the proportion of individual items of the income 
statement and how the proportions influence the company performance over the years.  
The proportion of selling, general and administration, the largest cost portion rises from 32% 
to 39%. Similarly, the proportion of the cost of sales increases in past five years, from 27% in 
2011 to 37% in 2015. Selling, general and administration also increased by 7% during this 
period. Therefore, the total costs were on a rise, which was steadily before 2013 and in the 
following two years fluctuate wildly. Comparing with data 73% in 2013, total costs hit the 
highest point in 2014 at 84%. Taking into account the growth of administrative costs, GSK 
decided to streamline the management team to carry out a number of restructuring plans. In 
2014, GSK said that in the next three years, the company will plan to cut the cost of £ 1 
billion (about $ 1.6 billion), which contributes a lot to the lowest ratio during the period at 57% 
in 2015.In generally, the proportion of profit before taxation hold steady at 25% and profit 
after taxation stands at 20%. While the proportion of the two parts respectively fell to 13% 
and 12% in 2014 and climbed to 44% and 35% in 2015, which was influenced by a big deal 
with Novartis, changing as other operating income and profit changing. Because the new 
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savings plan does not include the acquisition of the Novartis vaccine business segment and 
the establishment of consumer health joint venture. Royalty and other operating income hit 
the lowest point at -2% in 2014 then peaked at 34% in 2015. Similarly, operating profit hit the 
lowest point at 16% then peaked at 43%. 
 
4.1.2 Horizontal common-size analysis  
 
The horizontal common-size analysis also called trend analysis, is another form of the 
common size analysis, which is the time series analysis which is used for analysis the trend 
and the growth in the account over the period of time. To see the trend more clearly we use 
the original data in the annual report. As shown below. 
 
Table 4.4 Horizontal common-size analysis of balance sheet 
 2011 2012 2013 2014 2015 
Non-current assets 24,913  27,783  26,859  25,973  36,859  
Current assets 16,167  13,692  15,227  14,678  16,587  
Total assets 41,080  41,475  42,086  40,651  53,446  
Total liabilities 32,253  34,728  34,274  35,715  44,568  
Total equity 8,827  6,747  7,812  4,936  8,878  
Source: Own elaboration 
 
From the data of Tab. 4.4, we can get some information about horizontal common-size 
analysis of assets, liabilities and equity.We can make a graph form to represent this 
information, which allows us to get a more specified trend over the period. 
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Figure 4.4 Horizontal common-size analysis of balance sheet 
 
Source: Own elaboration 
 
Figure 4.4 clearly represents how the assets, liabilities and equity of GSK changed over 
this period. We can see almost each item related to assets plateau from 2011 to 2014. Except 
total equity was reduced by one-third, all fall from 8,827 to 4,936 during this period. The 
decrease arose principally from an increase in the pension deﬁcit and the impact of dividends 
paid out in the year. During the past five years, liabilities constantly increased, in which other 
non-current liabilities is £10,656 million at 31 December 2015 (2011 – £626 million). Based 
on the annual report, we can learn from annexes 1 that 2015 saw a dramatic increase in every 
item, and the other non-current liabilities include £3,549 million of contingent consideration 
payable, of which £3,110 million was in respect of the acquisition in 2012 of the former 
Shionogi-ViiV Healthcare joint venture, and £398 million was payable to Novartis in relation 
to the Vaccines acquisition during 2015. In addition, £6,287 million related to the present 
value of the estimated amount payable by GSK in the event of the full exercise of Novartis’ 
right to require GSK to acquire its 36.5% shareholding in the Consumer Healthcare Joint 
Venture. In the major deal with Switzerland's Novartis, which will see the two pharmaceutical 
group trade more than $20 billion of assets. The transaction, which includes GSK buying 
Novartis' vaccines business for 7.1 billion dollars, Novartis purchasing GSK's cancer drugs 
for 16 billion dollars, and the two groups tying up in consumer healthcare. 
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After analyzing the balance sheet, the absolute changes compared to 2011 in income 
statement is showed below. Calculation is based on equation 2.6. 
 
Table 4.5 Relative changes compared to 2011 in income statement 
 2011 2012 2013 2014 2015 
Turnover 100% -3% -3% -16% -13% 
Cost of sales 100% 8% 17% 0% 21% 
Selling, general and administration 100% -1% -4% -7% 5% 
Research and development 100% -1% -2% -14% -11% 
Royalty and other operating income 100% 166% 157% -166% 1270% 
Total costs 100% -3% -1% -1% -31% 
Gross profit 100% -5% -10% -54% 32% 
Non-operating revenues 100% -84% -44% -86% 39% 
Non-operating cost 100% 221% 216% 211% 214% 
Profit before taxation 100% -13% -14% -61% 37% 
Taxation 100% -13% -55% -94% -4% 
Profit after taxation for the year 100% -13% 3% -48% 53% 
Source: Own elaboration  
 
According to the results given in Tab. 4.5, it is clearly that royalty and other operating 
income and non-operating cost changed most intense, which is ten times and two times 
compared to the data in 2011. Two major causes are the decrease of the operating profit and 
other operating income. To do deep analysis on operating profit, compared with previous data, 
the drop in operating profit is attributable to the significant growth of other reconciling items 
between segment profit and operating profit, which comprise items not specifically allocated 
to segment profit. These include impairment and amortization of intangible assets, major 
restructuring charges, legal charges and expenses on the settlement of litigation and 
government investigations and certain other items related to major acquisition and disposal 
activity. As for other operating income, disposal of businesses and other assets, fair value 
premeasurements on contingent consideration recognized in business combinations, fair value 
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adjustments on derivative financial instruments underwent the bigger change. 
Based on part of results in Tab. 4.5, we made the followed Fig. 4.5. 
 
Figure 4.5 Relative changes compared to 2011 in income statement 
 
Source: Own elaboration  
In Fig. 4.5, the years from 2012 to 2013, each items fluctuation within a narrow range except 
non-profit revenues and taxation and the company is in a relatively stable state. While in 2014 
we saw a dramatic decline in almost every item and the go up in 2015. In 2015, the relative 
change compared to 2011 of the total cost was -31%, showing a striking decrease thanks to 
the major deal with Switzerland's Novartis, which lead to a rise in other operating income. As 
for the trade involving more than $20 billion of assets, the change also brings about the 
growth of Profit before taxation and Profit after taxation in 2015. 
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4.2 Financial ratio analysis 
 
This chapter we will evaluate the GSK Company’s financial situation in four aspects, 
profitability, liquidity, solvency and activity ratios. Before the ratio analysis, we will provide 
the general situation in pharmaceutical industry in the United Kingdom. 
Britain is the world's pharmaceutical industry, and the United States, Japan, one of the 
world three major drug development centre. According to the British Pharmaceutical Industry 
Association (ABPI) report, one in five of the world's top 100 prescription drugs is developed 
in the UK.  
The pharmaceutical sector is the main source of surplus, according to European 
federation of pharmaceutical industries and associations' report, the British pharmaceutical 
industry in 2014 exports 26,172 million pounds, the trade surplus of 64 million pounds. The 
research and development investment are also huge, in 2014 British pharmaceutical industry 
research and development investment reached 4,868 million pounds, accounting for 15,8% of 
European R&D investment. The United Kingdom also is home to GlaxoSmithKline and 
AstraZeneca, both of them are the world's top 10 largest pharmaceutical companies. Because 
of British extensive international investment cooperation, many of the world's top 
pharmaceutical groups has been attracted, such as Pfizer, Novartis, Lilly and Merck, all of 
them set up R & D centers and production sites in the UK. In 2014, the number of employees 
of British pharmaceutical companies reached 64,000. 
In order to have a more detailed understanding of GSK’s financial situation, in the 
following analysis, we will compare GSK’s financial ratios with the ratios in AstraZeneca and 
Johnson & Johnson. AstraZeneca plc is a British–Swedish multinational pharmaceutical and 
biopharmaceutical company with its headquarters in Cambridge, England. 
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4.2.1 Profitability ratios 
 
In this section, we use three basic ratios to analysis the profitability of GSK, in terms of 
return on assets (ROA) based on equation 2.9, return on equity (ROE) based on equation 2.10 
and net profit margin (NPM) based on equation 2.8. All data are from financial statements of 
GSK and AZN. 
The following table shows the GSK and AZN key profitability ratios between 2011 and 
2015. 
Table 4.6 Profitability ratio analysis of GSK 
 2011 2012 2013 2014 2015 
ROA GSK 13.3% 11.4% 13.4% 7.0% 15.7% 
ROE GSK 61.8% 70.3% 72.0% 57.4% 94.3% 
NPM GSK 19.9% 17.9% 21.2% 12.3% 35.0% 
ROA AZN 19.0% 11.7% 4.6% 2.1% 4.7% 
ROE AZN 42.7% 26.2% 11.1% 6.3% 15.3% 
NPM AZN 29.8% 24.0% 10.0% 4.7% 11.4% 
 Source: Own elaboration 
Figure 4.6 Profitability ratio analysis of GSK 
 
 Source: Own elaboration   
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First, we focus on the results of GSK given in the Tab. 4.6 show that the return on assets 
and not profit margin were around 13% and 20% respectively, while the return on equity in 
average was 70%. As it is shown in the Fig. 4.6, in the first three years, three indicators 
climbed at a modest pace. In year 2014 we saw a steep drop in all indicators, afterwards in 
2015, the upward trend is likely to resume, pushing key ratio to reach a new high level. The 
big fluctuation was caused by the three-part transaction with Novartis, which is a part of the 
company plan to accelerate strategy of making GSK a simpler, stronger and more balanced 
platform for long-term growth. 
To sum up, the profitability condition of GSK was in a good condition, and in present 
years, the company will have better develop prospects. 
Then we focus on the profitability ratios compare between GSK and AZN, with ROA as 
an example. Fig. 4.7 presents information about the changes in ROA ratio from 2011 to 2015. 
 
Figure 4.7 ROA compare between GSK and AZN 
 
 Source: Own elaboration 
 
It is clear in Fig. 4.7 that ROA ratio in AZN was higher than GSK’s in 2011 and 2012 and 
the gap became smaller; after 2012, GSK’s figure becomes greater than AZN’s one. In the Fig. 
4.7, we can see the trend of these two ratios, GSK and AZN both have shown the decreasing 
trend during the period between 2011and 2014 then show the sign of recovery in 2015. This 
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due to the reason that the two companies in recent years are in the strategic adjustment of the 
layout, the different is the change in GSK’s data is more gentle, whilst the recovery is faster, 
the growth is more robust, as shown in the Fig. 4.7, ROA of GSK reached the highest point in 
2015. The trend of ROE and NMP in these two companies is similar. 
 
4.2.2 Liquidity ratios 
 
Liquidity ratios are used to analysis a company's availability of cash to pay off its 
short-terms debts obligations. We take GSK Company’s financial statement 2011-2015 into 
the calculation as the following table and here are most common liquidity ratio 
includes:current ratio based on equation 2.11, quick ratio based on equation 2.12 and cash 
ratio based on equation 2.13. 
 
Table 4.7 Liquidity ratio analysis of GSK 
 2011 2012 2013 2014 2015 
Current ratio GSK 1.08  0.99  1.11  1.10  1.24  
Quick ratio GSK 0.82  0.70  0.83  0.79  0.88  
Cash ratio GSK 0.38  0.30  0.40  0.33  0.43  
Current ratio AZN 3.35  3.85  3.48  3.38  4.04  
Quick ratio AZN 3.24  3.70  3.36  3.27  3.90  
Cash ratio AZN 0.48  0.55  0.57  0.37  0.42  
 Source: Own elaboration 
 
Based on the part of data from the Tab. 4.7, the following graph was made. 
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Figure 4.8 Liquidity ratio analysis of GSK 
 
 Source: Own elaboration   
 
We will find a result from the Fig. 4.8 and Tab. 4.7 that despite the fluctuation, the 
general trend of liquidity ratios was upward. Generally, perfect financial companies, their 
current assets should be much higher than the current liabilities, at least not less than 1: 1, 
generally considered greater than 2: 1 is more appropriate. According to the results given in 
the Tab. 4.7, the current ratios of GSK are higher than 1 in four years, except 2012.The 
current ratio in 2015 was 1.24 compared 1.08 in 2011, showing an increase of 0.16.As the 
quick ratio, it is usually believed that if the ratio is less than 1, the short-term solvency is low. 
And the minimum quick ratio is 0.5 if it keeps at 1: 1, the safety of current liabilities is more 
secure. Although the general trend of the quick ratio in GSK was upward, the quick ratios 
were still lower than 1, fluctuating mildly around 0.8. Similarly, the cash ratio ranges from 0.3 
to 0.43. 
Overall, the liquidity of current assets is getting better, even though the stricter 
acquirement, such as quick ratio and cash ratio had not been met. 
After analyzing the liquidity ratio in GSK, we will have a look for different between the 
two companies. As shown in the table 4.7, the value of current ratio and quick ratio of AZN 
are between 3 and 4 while the ratio in GSK is about 1, which means AZN’s liquidity situation 
is far better than GSK. However, the two ratios are not the higher the better, excessive assets 
relative to the current liabilities indicating that it may be the backlog of inventory or too much 
cash or both.In AZN, it due to the excessive inventories and trade and other receivables, this 
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may pose a threat to the company’s future development. 
The gap between cash ratios is relatively narrow, as the Fig.4.9 shown below: 
 
Figure 4.9 Cash ratio compare between GSK and AZN 
 
 Source: Own elaboration 
 
As shown in Fig. 4.9, the cash ratios of the two companies are relatively low. 
The first three years, the cash ratios of AZN are in 0.5 or so, which is very optimistic, 
2014 saw a dramatic drop and in 2015 the ratio go up again, but still maintained at a low level, 
GSK’s cash ratio has a slight change in the past five years, in general, the situation is 
improving. The two companies should focus on the cash ratios change to prevent the situation 
that cash shortage leads to cash flow dilemma even capital chain rupture. 
 
4.2.3 Solvency ratios 
 
Solvency ratios evaluate the ability of an enterprise to repay its long-term debt with its 
assets.  
Based on equation 2.14, 2.15 and 2.16, some key solvency ratios of GSK are calculated 
from data in a financial statement during 2011 to 2015. 
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Table 4.8 Solvency ratio analysis of GSK 
 2011 2012 2013 2014 2015 
Debt to assets ratio GSK 0.79  0.84  0.81  0.88  0.83  
Debt to equity ratio GSK 3.65  5.15  4.39  7.24  5.02  
Interest coverage GSK 9.63  8.28  8.67  4.08  13.90  
Debt to assets ratio AZN 0.56 0.55 0.58 0.66 0.69 
Debt to equity ratio AZN 1.25 1.24 1.40 1.98 2.25 
Interest coverage AZN 21.86 14.06 6.60 1.29 2.85 
Source: Own elaboration 
 
According to Tab. 4.8, we made Figure 4.9 as follow. 
 
Figure 4.9 Solvency ratio analysis of GSK 
 
 Source: Own elaboration 
 
From Tab. 4.8 and Fig. 4.9, we can see that the debt-to-assets ratio plateau for 5 years 
around 0.8, in other words, 80% of the company’s total assets are raised through borrowing 
thus the company has little net assets or solvency. On one side it means the ability of 
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companies of using funds of the creditors to carry out business activities is great and on the 
other hand, it also reflects the degree of security of creditors to issue loans is relatively low. 
Despite the debt to equity ratio and interest coverage fluctuated wildly during the five-year 
period, especially in 2014 and 2015 (because of three-part Novartis transaction), in general, 
they go up. 
To summaries, the proportion of debt in all assets is increasing, which pose a threat to 
financial health, while the interest coverage peaked at 14 or so in 2015 after a transaction with 
Novartis, there is no need to worry about financial cost in recent years. 
To compare the two company’s solvency ratio, here is a figure about two company’s 
interest coverage ratio in detail. 
 
Figure 4.10 Interest coverage compare between GSK and AZN 
 
 Source: Own elaboration 
 
From the information in Fig 4.10, despite the different fluctuation, the trend of two 
company is similar; the ratios decrease in first four years, then rise up. During the whole 
period, the interest coverage in GSK and AZN are in the very excellent situation. Combined 
with other solvency ratios, through the Tab. 4.8, we can also clearly find out the debt to asset 
ratio and debt to equity ratio in GSK is higher than the ratio in AZN, especially the debt to 
equity ratio is far more than AZN, which due to the GSK’s high proportion of liability in 
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company’s capital structure.In theory, the higher asset-liability ratio, the bigger financial risk. 
When there is insufficient cash flow, the potential funding strand breaks, not timely debt 
service, leading to the bankruptcy case. The high asset-liability ratio will lead to further 
financing costs. Both banks and investors have a certain demand for asset-liability ratios. But 
a high level of interest coverage indicates the GSK has enough profit to pay interest expense, 
with high profitability as security. Thus may be the reason why the long-term borrowing 
occupies a large proportion of its total assets. 
 
4.2.4 Activity ratios 
 
The activity ratios are financial ratios used to measure the efficiency of the company's 
asset management. 
The results given in the following table represent the ratio of the inventory turnover based 
on 2.17 accounts receivable turnover based on 2.18 and total asset turnover based on 2.19 in 
GSK during fast five years. 
 
Table 4.9 Activity ratio analysis of GSK and AZN 
 2011 2012 2013 2014 2015 
Inventory turnover GSK 7.1  6.7  6.8  5.4  5.1  
Accounts receivable turnover GSK 4.9  5.0  4.9  5.0  4.3  
Total assets turnover GSK 0.7  0.6  0.6  0.6  0.4  
Inventory turnover AZN 18.1  13.6  13.5  13.3  11.0  
Accounts receivable turnover AZN 3.8  3.7  3.3  3.6  3.6  
Total assets turnover AZN 0.6  0.5  0.5  0.4  0.4  
 Source: Own elaboration 
 
In the Tab. 4.9, we find out the differences in total assets turnover is relatively small, at 
around 0.5, while the inventory turnover and accounts turnover is shown in the following 
graph. 
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Figure 4.11 Comparison between GSK and AZN 
 
 Source: Own elaboration  
 
As it is shown in the Fig. 4.11, AZN has higher inventory ratio whilst GSK has a higher 
accounts receivable ratio. Higher inventory usually means that a retailer that is able to turn 
over, or sell, its inventory more often than a rival is a better operator. The receivables turnover 
ratio indicates the efficiency with which a firm manages the credit it issues to customers and 
collects on that credit. Because accounts receivable are money owed on a credit agreement 
without interest, by maintaining accounts receivable firms are indirectly extending 
interest-free loans to their clients. As such, because of the time value of money principle, a 
firm loses more money the longer it takes to collect on its credit sales.  
Based on the data from Tab. 4.9, we made Fig. 4.12 here as follows: 
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Figure 4.12 Activity ratio analysis of GSK 
 
Source: Own elaboration 
 
From the Tab. 4.9 and the Fig. 4.12, we can find that all three activity ratios decrease in 
general during 2011 and 2015.Inventory turnover saw the steepest decrease from 7.1 in 2011 
to 5.1 in 2015. Similarly, total assets turnover dropped to 0.4 by a decrease of 0.3 compared to 
the ratio in 2011. In general, the faster the inventory turnover, the lower the occupancy level 
of inventory, the stronger the liquidity, the faster the inventory is converted to cash or 
receivables, indicating that the more efficient inventory management. Raising the inventory 
turnover rate can improve the company's liquidity. The decrease of inventory turnover means 
the decline of inventory management efficiency. Accounts receivable turnover stayed at 
around 5 for four years except 2015, in which the tario shirked to 4.3. 
Though the trend was downward, the inventory turnover and accounts receivable turnover 
were still in an excellent condition.As the total assets turnover saw a steep drop, it should be 
paid more attention. 
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4.3 Pyramidal decomposition 
 
Pyramidal decomposition analysis (DuPont analysis) enables to the analysis of the 
financial situation of enterprises synthetically, by using the relationship between several major 
financial ratios. According to DuPont analysis, it is an expression that breaks return on equity 
(ROE) down into three parts: profit margin, total asset turnover and financial leverage. It 
means that ROE is affected by three items: Operating efficiency, which is measured by profit 
margin; asset use efficiency, which is measured by total asset turnover; financial leverage, 
which is measured by the equity multiplier. 
In this part, we use decomposition method of gradual change to analyze indicators and 
evaluation of how these component ratios affect the ROE of GSK during 2011 to 2015.The 
absolute change and Index of change of ROE are shown in the Tab. 4.10 as follows: 
 
Table 4.10 Analysis of ROE 2011-2015 
 2011 2012 2013 2014 2015 
EAT 5458 4744 5628 2831 8372 
Total equity 8827 6747 7812 4936 8878 
Operating profit 7807 7392 7208 3597 10322 
Total assets 41080 41475 42086 40651 53446 
ROE 61.8% 70.3% 72.0% 57.4% 94.3% 
Absolute change × 8.5% 1.7% -14.7% 36.9% 
Index of change × 113.7% 102.5% 79.6% 164.4% 
Source: Own elaboration 
 
According to Tab. 4.10, we can see that the absolute change of return on equity is positive in 
four years except 2014. In general, the return on equity was increased during the period the 
index change is stable in first two years; then dropped a lot in 2014,and the ratio in 2015 is 
really high, which are over 150%. It means the main trend about return on equity was upward, 
but 2014 saw a drop to 57.4%. From this value we can see that GSK Company has a robust 
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return on equity during the completion of the proposed three-part Novartis transaction and 
further restructuring and innovation. It means that GSK Company can deliver a stable return 
on equity and steady earning grows during this period. After 2015, finishing the transaction 
with Novartis, the situation may even get better. A strong return on equity indicated that GSK 
Companycan sustain its competitive advantage and earnings growth. Although the ROE was 
decreased in 2014, the percentage of ROE was higher than 50%.  
We have known that thefour possible ways of quantification the effect of each factor change. 
In this work, we will only focus on one method, which is the method of gradual changes to 
analyze. 
 
Table 4.11 Pyramidal decomposition of ROE in GSK 
 2011 2012 Δa ΔROE ORDER 
EAT/REV 0.20  0.18  -2.0% -6.1% 2 
REV/ASSETS 0.67  0.64  -2.9% -2.5% 3 
ASSETS/EQUITY 4.65  6.15  149.3% 17.1% 1 
SUM    8.5%  
 2012 2013 Δa ΔROE ORDER 
EAT/REV 0.18  0.21  3.3% 12.9% 1 
REV/ASSETS 0.64  0.63  -0.7% -1.0% 3 
ASSETS/EQUITY 6.15  5.39  -76.0% -10.2% 2 
SUM    1.7%  
 2013 2014 Δa ΔROE ORDER 
EAT/REV 0.21  0.12  -8.9% -30.3% 1 
REV/ASSETS 0.63  0.57  -6.4% -4.2% 3 
ASSETS/EQUITY 5.39  8.24  284.8% 19.8% 2 
SUM    -14.7%  
 2014 2015 Δa ΔROE ORDER 
EAT/REV 0.12  0.35  22.7% 105.8% 1 
REV/ASSETS 0.57  0.45  -11.8% -34.1% 3 
ASSETS/EQUITY 8.24  6.02  -221.6% -34.7% 2 
SUM    36.9%  
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Source: Own elaboration 
Figure 4.13 Pyramidal decomposition of ROE in GSK 
 
Source: Own elaboration 
 
In Tab 4,11 and Fig. 4.13 we can find out the order of influential, except the period from 2011 
to 2012, net profit margin contributed most to ROE change, and the change of net profit 
margin became more violent, in 2015, the changes of net profit margin contributed 105.8% in 
total ROE change. Therefore, the company should focus more on the ability of making profit 
and decrease the costs to improve both revenues and earnings after tax. The followed one is 
financial leverage and the smallest change comes from asset turnover in the whole period. 
Because of its high level of profitability the company normally have stable, predictable cash 
flows and typically carry high debt levels. Nevertheless, GSK should take precautions of 
financial leverage changes. 
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5 Conclusion 
 
In this thesis, we focused on the financial analysis of GSK company, before that, we 
introduced the source of data, the three main statements: balance sheet, income statement and 
cash flow statement, then explained three methods of financial analysis:common-size analysis, 
financial ratio analysis and pyramidal decomposition. 
The aim of the thesis was to evaluate the financial performance of GSK company for the 
by the help of annual reports for period 2011 - 2015. 
This thesis analyzed the GSK Company’s ability to financing, make profits, repaid the 
funds and other abilities in three methods, including common-size analysis, financial ratio 
analysis and pyramidal decomposition. Overall, it shows a future perspective of the company. 
By analyzing the financial statements of GSK Company, we found there are three main 
periods in past five years. Before 2014, GSK Company kept a quite stable state, though its 
revenue decreasing slightly, considering the increasing costs. In 2014, after proposing 
three-part transaction with Novartis, GSK Company had more volatile changes in reporting 
materials. On March 2015, GSK and Novartis announced the completion of their major 
three-part transaction. In 2015 annual report, the most financial analysis indicators go back to 
normal and even better.  
In the common-size analysis we can find that the assets structure keeps stable in general 
during the last five years. And the liabilities account for around 80%~90% in total assets and 
the general trend of liabilities proportion was upward. Despite the fluctuation, the general 
trend of equity proportion was downward. The proportion of shareholder’s equity, the largest 
equity composition part, dropped from 20% to 10%. 2015 saw a dramatic increase in every 
item due to the major deal with Switzerland's Novartis, which will see the two pharmaceutical 
group trade more than $20 billion of assets.The transaction, which includes GSK buying 
Novartis' vaccines business for 7.1 billion dollars, Novartis purchasing GSK's cancer drugs 
for 16 billion dollars, and the two groups tying up in consumer healthcare, was unveiled in 
April.  
From financial ratio analysis, we can learn that the profitability condition of GSK was in  
a good condition, and in present years, the company will have better develop prospects.In 
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addition, the liquidity of current assets is getting better, even though the stricter acquirement, 
such as quick ratio and cash ratio had not been met.From solvency ratios analysis, we find 
that the proportion of debt in all assets is increasing, which pose a threat to financial health, 
but after the transaction with Novartis the interest coverage peaked at 14 or so in 2015, there 
is no need to worry about financial cost in recent years. As for activity ratio, though the trend 
was downward, the inventory turnover and accounts receivable turnover were still in an 
excellent condition. As the total assets turnover saw a steep drop, it should be paid more 
attention. 
From the pyramidal decomposition of return on equity analysis, we could find out after the 
transaction with Novartis the ROE reached 36.9%, contributed by 109% increase in net profit 
margin. 
The summary of this thesis suggests that a big and stable developing company, with strong 
profitability and good prospects. But they still should pay attention to its liquidity, especially 
the quick ratio and cash ratio. After the big transaction with Novartis, GSK would focus more 
on vaccines and consumer healthcare. They should pay attention to the distribution of assets  
in different areas. 
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Annexe 1 Balance sheet 
Consolidated balance sheet 
 
2011 
£m 
2012 
£m 
2013 
£m 
2014 
£m 
2015 
£m 
Non-current assets      
Property, plant and equipment 8,748  8,776  8,872  9,052  9,668  
Goodwill 3,754  4,359  4,205  3,724  5,162  
Other intangible assets 7,802  10,161  9,283  8,320  16,672  
Investments in associates and joint ventures 560  579  323  340  207  
Other investments  590  787  1,202  1,114  1,255  
Deferred tax assets 2,849  2,385  2,084  2,688  2,905  
Derivative financial instruments 85  54  1  - - 
Other non-current assets  525  682  889  735  990  
Total non-current assets  24,913  27,783  26,859  25,973  36,859  
Current assets      
Inventories 3,873  3,969  3,900  4,231  4,716  
Current tax recoverable  85  103  129  138  180  
Trade and other receivables  5,576  5,242  5,442  4,600  5,615  
Derivative financial instruments  70  49  155  146  125  
Liquid investments 184  81  66  69  75  
Cash and cash equivalents  5,714  4,184  5,534  4,338  5,830  
Assets held for sale 665  64  1  1,156  46  
Total current assets  16,167  13,692  15,227  14,678  16,587  
Total assets 41,080  41,475  42,086  40,651  53,446  
Current liabilities      
Short-term borrowings  -2,698  -3,631  -2,789  -2,943  -1,308  
Trade and other payables  -7,359  -8,054  -8,317  -7,958  -9,191  
Derivative financial instruments -175  -63  -127  -404  -153  
Current tax payable -1,643  -1,374  -1,452  -945  -1,421  
Short-term provisions -3,135  -693  -992  -1,045  -1,344  
Total current liabilities  -15,010  -13,815  -13,677  -13,295  -13,417  
Non-current liabilities      
Long-term borrowings -12,203  -14,671  -15,456  -15,841  -15,324  
Deferred tax liabilities  -822  -1,004  -693  -445  -1,522  
Pensions and other post-employment 
benefits  
-3,091  -3,105  -2,189  -3,179  -3,229  
Other provisions -499  -699  -552  -545  -420  
Derivative financial instruments -2  -2  -3  -9  - 
Other non-current liabilities  -626  -1,432  -1,704  -2,401  -10,656  
Total non-current liabilities  -17,243  -20,913  -20,597  -22,420  -31,151  
Total liabilities -32,253  -34,728  -34,274  -35,715  -44,568  
2 
 
Net assets 8,827  6,747  7,812  4,936  8,878  
Equity      
Share capital 1,387  1,349  1,336  1,339  1,340  
Share premium account 1,673  2,022  2,595  2,759  2,831  
Retained earnings 3,370  652  913  -2,074  -1,397  
Other reserves  1,602  1,787  2,153  2,239  2,340  
Shareholders’ equity 8,032  5,810  6,997  4,263  5,114  
Non-controlling interests  795  937  815  673  3,764  
Total equity 8,827  6,747  7,812  4,936  8,878  
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Annexe 2 Income Statement 
Consolidated income statement 
 
2011 
£m 
2012 
£m 
2013 
£m 
2014 
£m 
2015 
£m 
Turnover 27,387 26,431  26,505  23,006  23,923  
Cost of sales -7,332 -7,894  -8,585  -7,323  -8,853  
Gross profit 20,055 -18,537  17,920  15,683  15,070  
Selling, general and administration -8,826 -8,739  -8,480  -8,246  -9,232  
Research and development -4,009 -3,968  -3,923  -3,450  -3,560  
Royalty income - 306  387  310  329  
Other operating income 587 1,256  1,124  -700  7,715  
Operating profit 7,807 7,392  7,208  3,597  10,322  
Finance income 90 79  61  68  104  
Finance costs -799 -808  -767  -727  -757  
Profit on disposal of interest in associates 585 - 282  - 843  
Share of after tax profits of associates and joint 
ventures 
15 29  43  30  14  
Profit before taxation 7,698 6,692  6,647  2,968  10,526  
Taxation -2,240 -1,948  -1,019  -137  -2,154  
Profit after taxation for the year 5,458 4,744  5,628  2,831  8,372  
Profit attributable to non-controlling interests 197 179  192  75  -50  
Profit attributable to shareholders 5,261 4,565  5,436  2,756  8,422  
 5,458 4,744  5,628  2,831  8,372  
Basic earnings per share (pence) 104.6P 92.9P 112.5P 57.3P 174.3P 
Diluted earnings per share (pence) 103.2P 91.5P 110.5P 56.7P 172.3P 
 
1 
 
Annexe 3 Cash Flow  
Consolidated cash flow statement 
 
2011 
£m 
2012 
£m 
2013 
£m 
2014 
£m 
2015 
£m 
Cash flow from operating activities      
Profit after taxation for the year  5,458  4,744  5,628  2,831  8,372  
Adjustments reconciling profit after tax to 
operating cash flows  
2,255  1,304  2,871  3,453  -3,741  
Cash generated from operations 7,713  6,048  8,499  6,284  4,631  
Taxation paid  -1,463  -1,673  -1,277  -1,108  -2,062  
Net cash inflow from operating activities 6,250  4,375  7,222  5,176  2,569  
Cash flow from investing activities      
Purchase of property, plant and equipment  -923  -1,051  -1,188  -1,188  -1,380  
Proceeds from sale of property, plant and 
equipment 
100  68  46  39  72  
Purchase of intangible assets  -405  -469  -513  -563  -521  
Proceeds from sale of intangible assets 237  1,056  136  330  236  
Purchase of equity investments  -76  -229  -133  -83  -82  
Proceeds from sale of equity investments 68  28  59  205  357  
Purchase of businesses, net of cash 
acquired  
-264  -2,235  -247  -104  -3,541  
Disposal of businesses  - - 1,851  225  10,246  
Investments in associates and joint 
ventures   
-35  -99  -8  -9  -16  
Proceeds from disposal of subsidiary and 
interest in associate 
1,034  - 429  1  564  
(Increase)/decrease in liquid investments 30  224  15  1  -2  
Interest received 97  30  59  63  99  
Dividends from associates and joint 
ventures 
25  46  18  5  5  
Net cash inflow/(outflow) from investing 
activities 
-112  -2,631  524  -1,078  6,037  
Cash flow from financing activities      
Proceeds from own shares for employee 
share options 
45  58  - - - 
Shares acquired by ESOP Trusts -36  -37  -45  -95  -99  
Issue of share capital  250  356  585  167  73  
Purchase of own shares for cancellation or 
to be held as Treasury shares  
-2,191  -2,493  -1,504  -238  - 
Purchase of non-controlling interests - -14  -588  -679  - 
Increase in long-term loans - 4,430  1,913  1,960  - 
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Increase in short-term loans 45  1,743  - - - 
Repayment of short-term loans  -8  -2,559  -1,872  -1,709  -2,412  
Net repayment of obligations under 
finance leases  
-38  -35  -31  -23  -25  
Interest paid  -769  -779  -749  -707  -762  
Dividends paid to shareholders -3,406  -3,814  -3,680  -3,843  -3,874  
Distributions to non-controlling interests  -234  -171  -238  -205  -237  
Other financing cash flows  110  -36  -64  -13  233  
Net cash outflow from financing activities  -6,232  -3,351  -6,273  -5,385  -7,103  
Increase/(decrease) in cash and bank 
overdrafts  
-94  -1,607  1,473  -1,287  1,503  
Cash and bank overdrafts at beginning of 
year  
5,807  5,605  3,906  5,231  4,028  
Exchange adjustments  -108  -92  -148  84  -45  
Increase/(decrease) in cash and bank 
overdrafts  
- -1,607  1,473  -1,287  1,503  
Cash and bank overdrafts at end of year  5,605  3,906  5,231  4,028  5,486  
Cash and bank overdrafts at end of year 
comprise: 
     
Cash and cash equivalents 5,714  4,184  5,534  4,338  5,830  
Overdrafts  -109  -278  -303  -310  -344  
 5,605  3,906  5,231  4,028  5,486  
 
